Moderna is partnering with artificial intelligence-focused precision medicine company Caris Life Science to support Moderna's oncology initiatives.
Through the multiyear partnership, Moderna will use Caris' library of deidentified data to advance the company's oncology pipeline. Additionally, the partnership will focus on facilitating clinical trial design, discovering new biomarkers and characterizing resistance mechanisms, according to an Oct. 24 Caris news release.
Financial terms of the partnership were not disclosed.
"We are thrilled to partner with Moderna to impact and advance the field of cancer treatment with mRNA medicines, with a common goal of improving patient lives," David Spetzler, PhD, president of Caris Life Sciences, said in the news release. "The aggregate strength of our combined molecular, data science and therapeutics technologies will support the predictive modeling of patient responses to therapies, and more generally, may help improve the probability of technical and regulatory success of Moderna's innovative medicines."